Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the Phase III BREAKWATER trial led by researchers at The University of Texas MD Anderson Cancer Center.

High-risk Patients for Colorectal Cancer Lack Knowledge About Colonoscopy

Many clinicians rely on self-reports from their high-risk patients about their need and proper interval for repeat surveillance colonoscopy. Researchers analyzed data over four years to explore the knowledge of these high-risk patients. Twenty-eight percent were unaware of either the need for a repeat colonoscopy or the proper surveillance interval. Of these, 16.6 percent were unaware of the proper three-year interval to obtain a follow-up surveillance colonoscopy. Also, 12 percent were not even aware that they required a follow-up surveillance colonoscopy.